Andecaliximab

Drug Overview

The medication known as andecaliximab (formerly referred to by its laboratory code GS-5745) is an investigational, highly specialized type of immunotherapy called a monoclonal antibody. It is designed to disrupt the structural support system that allows tumors to grow and spread. Unlike traditional chemotherapy that kills cells directly, andecaliximab targets an enzyme in the environment surrounding the tumor, essentially trying to “starve” the cancer of the space and signals it needs to expand.

In clinical oncology, canakinumab is classified as an MMP-9 Inhibitor. Matrix metalloproteinases (MMPs) are enzymes that act like microscopic “scissors,” cutting through the body’s connective tissue. By blocking these scissors, andecaliximab aims to keep the tumor “boxed in” and more vulnerable to other treatments.

• Generic Name: Andecaliximab.
• US Brand Names: None yet. It is currently an investigational drug.
• Drug Class: Matrix Metalloproteinase-9 (MMP-9) Inhibitor / Monoclonal Antibody.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of 2026, it has been evaluated in Phase II and Phase III clinical trials, primarily for gastrointestinal cancers, but it has not yet received full FDA approval.

What Is It and How Does It Work? (Mechanism of Action)

Adalimumab is a “Smart Drug” that functions as a protein blockade. To understand its action at the molecular level, we must look at how tumors remodel their neighborhood.

The Role of MMP-9

MMP-9 is an enzyme that breaks down the Extracellular Matrix (ECM)—the “glue” that holds our cells together. While healthy cells use MMP-9 for wound healing, cancer cells hijack it to clear a path through tissue, allowing the tumor to expand and enter the bloodstream (metastasis).

Molecular Level Mechanisms

1. Selective Inhibition: Andecaliximab is a “highly selective” antibody. It binds only to the MMP-9 enzyme, leaving other MMP enzymes (which are necessary for healthy body functions) alone.
2. Anti-Angiogenesis: MMP-9 releases “Growth Factors” (like VEGF) that are trapped in the tissue. By blocking MMP-9, andecaliximab prevents the release of these factors, which stops the tumor from growing its own blood supply.
3. Disrupting the “Shield”: Tumors use MMP-9 to create a pro-inflammatory environment that hides them from the immune system. Andecaliximab helps break down this “shield,” potentially allowing a patient’s own T-cells to find and attack the cancer.
4. Inhibition of EMT: It interferes with the Epithelial-Mesenchymal Transition (EMT), a process where cancer cells transform to become more mobile. Blocking MMP-9 helps “anchor” the cancer cells in place.

FDA Approved Clinical Indications

Andecaliximab is an investigational agent and is currently available only through clinical trials. It has been most extensively studied in the following areas:

Oncological Uses (In Clinical Trials):

• Gastric and Gastroesophageal Junction Adenocarcinoma: Studied in combination with mFOLFOX6 chemotherapy.
• Pancreatic Cancer: Investigated for its ability to prevent the rapid spread of pancreatic tumors.
• Advanced Solid Tumors: Used in “basket trials” for various cancers that produce high levels of MMP-9.

Non-oncological Uses:

• Inflammatory Bowel Disease (IBD): Early trials (such as for Ulcerative Colitis) investigated its ability to stop tissue destruction in the gut, though research has primarily shifted back to oncology.

Dosage and Administration Protocols

In clinical trial settings, andecaliximab is administered as an infusion. The dose is usually calculated based on the patient’s body weight.

Clinical Efficacy and Research Results

Recent clinical data (2020–2026) has provided deep insights into which patients benefit most from this therapy.

• GAMMA-1 Trial Results: In a major Phase III study for gastric cancer, the addition of andecaliximab to chemotherapy showed a modest improvement in Progression-Free Survival (PFS) in specific subgroups, particularly in patients over the age of 65.
• Biomarker Discovery: Research indicates that the drug is most effective in tumors that show “High MMP-9 Expression.” Modern trials are now pre-screening patients for this protein to ensure higher success rates.
• Safety Milestones: Unlike older, non-selective MMP inhibitors that caused severe joint pain, andecaliximab’s high selectivity has made it much safer and better tolerated in long-term studies.

Safety Profile and Side Effects

Andecaliximab is generally well-tolerated, especially when compared to standard chemotherapy.

Common Side Effects (>10%):

• Fatigue: A general sense of tiredness.
• Nausea: Usually mild.
• Decreased Appetite: A common side effect when used in gastrointestinal cancer patients.
• Peripheral Edema: Mild swelling in the ankles or feet.

Serious Adverse Events:

• Infusion Reactions: Rare cases of fever or chills during the IV.
• Musculoskeletal Pain: While rare with this specific drug, some patients report mild joint or muscle aches.
• Black Box Warning: There is currently no FDA Black Box Warning for andecaliximab.
• Management Strategies: Side effects are usually managed with standard supportive care. Because it is an antibody, there is no risk of the hair loss or severe mouth sores associated with chemotherapy.

Research Areas

In the realm of Stem Cell and Regenerative Medicine, andecaliximab is being studied for its effect on the “Stem Cell Niche.” MMP-9 is known to play a role in releasing Hematopoietic Stem Cells from the bone marrow into the blood. Researchers are investigating if andecaliximab can help “stabilize” the bone marrow during cancer treatment, potentially protecting the patient’s healthy stem cell reserves while the cancer is being targeted. This regenerative focus aims to help patients recover their immune systems faster after intensive therapy.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• MMP-9 Biomarker Testing: To see if the tumor produces the protein that the drug targets.
• Liver and Kidney Function: Standard blood panels to ensure overall health.
• Baseline Imaging (CT/PET): To measure the tumor size before starting.

Precautions During Treatment:

• Monitoring Infusions: Patients should be monitored for signs of an allergic reaction during the first few infusions.
• Joint Health: Report any new or unusual joint stiffness to your oncology team.

“Do’s and Don’ts” List:

• DO keep a diary of your energy levels, as fatigue is the most common side effect.
• DO stay hydrated to help your body process the infusion.
• DON’T miss your scheduled infusions; the drug works best when levels are kept steady in the blood.
• DON’T start any new intensive physical therapy programs without consulting your doctor, to ensure your joints and tissues are responding well to the treatment.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Andecaliximab is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.